| Long name: |
Insulin Receptor alpha Antibody |
| Also known as: |
Insulin Receptor alpha Antibody |
| Category: |
Primary Antibodies |
| Conjugation: |
Unconjugated |
| Target Antigen: |
Insulin Receptor alpha |
| Specificity: |
This is a highly specific antibody against Insulin Receptor alpha |
| Modification(s): |
None |
| Modification site(s): |
Unmodified antibody |
| Clonality: |
Polyclonal antibody |
| Clone number: |
Polyclonal antibody |
| Concentration: |
1ug per 1ul |
| Immunogen range: |
700-750/1382 |
| Subcellular location: |
Extracellular |
| Source: |
This antibody was obtained by immunization of the host with KLH conjugated synthetic peptide derived from human Insulin Receptor alpha |
| Gene ID number: |
3643 |
| Swiss Prot: |
P06213 |
| Tested Applications: |
IF(IHC-P), IHC-P, WB |
| Recommended dilutions: |
IF(IHC-P)(1:50-200), IHC-P(1:100-500), WB(1:100-1000) |
| Cross reactivity: |
Mouse, Rat, Human |
| Cross reactive species details: |
not every possible cross-reactivity is known, Due to limited amount of testing and knowledge |
| Background of the target antigen: |
2, 3, 4, 4), 5)-triphosphate (PIP3), AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway, Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin, Binding of insulin leads to phosphorylation of several intracellular substrates, Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, CBL and other signaling intermediates, Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosines residues, GAB1, Moreover, Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, SHC, The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport, a lipid second messenger, activated AKT/PKB is responsible for: anti-apoptotic effect of insulin by inducing phosphorylation of BAD, and the Ras-MAPK pathway, including, including the p85 regulatory subunit of PI3K and SHP2, insulin receptor substrates (IRS1, regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors, such as PDPK1 and subsequently AKT/PKB, upon insulin stimulation, which activates several PIP3-dependent serine/threonine kinases, which is responsible for most of the metabolic actions of insulin, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation, Receptor tyrosine kinase which mediates the pleiotropic actions of insulin |
| Purification method: |
This antibody was purified via Protein A |
| Storage conditions: |
50% glycerol and 0, Store at -20°, 09% sodium azide, C for up to 1 year, Keep the antibody in aqueous buffered solution containing 1% BSA |
| Synonym names: |
CD220, INSR, IR, Insulin receptor, HHF5 |
| Properties: |
C, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Unconjugated Antibodies they should be stored frozen at - 24° |
| Gene target: |
Insulin Receptor alpha |
| Short name: |
Insulin Receptor alpha Antibody |
| Technique: |
antibodies against human proteins, antibodies for, Antibody |
| Alternative name: |
Insulin Receptor a (Antibody to) |
| Alternative technique: |
antibodies |